FDA Warns on Compounded GLP-1s; Hims & Hers Slides 3.85%
HIMS has more than doubled off its 52-week low of $13.74.
Summary
The FDA issued a warning about severe health risks from unapproved compounded GLP-1 weight-loss drugs, citing 990 adverse event reports for compounded semaglutide and 730 for tirzepatide. Hims & Hers, which sells compounded weight-loss medications, saw its stock drop 3.85% on the news. The warning includes import alert 66-80 targeting non-compliant foreign ingredient manufacturers. This follows prior regulatory pressure on Hims & Hers, including an FTC lawsuit over data sharing and a Visa notice over customer complaints. The FDA's crackdown could directly threaten Hims & Hers' compounded GLP-1 revenue stream, a key growth driver. Watch for any company response or further regulatory actions.
At the time of this announcement, HIMS was trading at $28.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $13.74 to $65.30. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.